Industry overview
The Manufacture of basic pharmaceutical products and pharmaceutical preparations sector across Netherlands comprises approximately 252 enterprises employing about 14,471 people and generating €7.3 bn in net turnover in 2020. The average enterprise size is – employees per firm. This is a useful yardstick when assessing whether your own operation sits within the typical scale band of the sector.
Profitability
With a robust operating margin of 17.1% of revenue in 2020, the sector reports €1.3 bn of gross operating surplus (Eurostat's EBITDA-equivalent, before depreciation). This figure provides the headline benchmark against which an individual operator can sanity-check their own bottom line, values significantly below indicate cost or pricing pressure, those above suggest competitive advantage worth defending.
Cost structure
The Manufacture of basic pharmaceutical products and pharmaceutical preparations cost mix is reasonably balanced: cost of revenue at 68.9%, personnel at 15.8% and energy at – of turnover. Without a single dominant cost driver, margin management requires attention across the full operating envelope rather than focus on any one line.
Trend & trajectory
Over the period 2009 to 2020 the operating margin moved from 19.7% to 17.1% (-2.6 percentage points), a deteriorating trajectory that warrants attention. Sectors with stable or improving margins tend to reflect successful pass-through of input costs and disciplined capacity management; declining margins typically point to either over-supply or a structural cost squeeze that warrants strategic review.